EUDA Health (NASDAQ:EUDA) Stock Rating Lowered by Zacks Research

EUDA Health (NASDAQ:EUDA) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Monday,Zacks.com reports.

Several other equities research analysts have also recently issued reports on the stock. Greenridge Global cut their price objective on shares of EUDA Health from $120.00 to $55.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Weiss Ratings reiterated a “sell (d)” rating on shares of EUDA Health in a report on Friday, January 9th. One research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, EUDA Health presently has a consensus rating of “Reduce” and an average target price of $55.00.

EUDA Health Trading Up 28.6%

Shares of EUDA stock opened at $9.13 on Monday. The company’s 50-day moving average price is $19.87 and its 200-day moving average price is $38.08. The stock has a market cap of $17.26 million, a price-to-earnings ratio of -76.08 and a beta of -0.11. EUDA Health has a twelve month low of $6.42 and a twelve month high of $86.00.

Institutional Investors Weigh In On EUDA Health

An institutional investor recently raised its position in EUDA Health stock. Citadel Advisors LLC raised its position in EUDA Health Holdings Limited (NASDAQ:EUDA) by 57.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,631 shares of the company’s stock after acquiring an additional 16,321 shares during the quarter. Citadel Advisors LLC owned approximately 0.12% of EUDA Health worth $78,000 as of its most recent SEC filing. 4.35% of the stock is currently owned by institutional investors.

About EUDA Health

EUDA Health, Inc (NASDAQ:EUDA) is a healthcare technology company focused on the development and commercialization of digital health solutions and energy-based medical devices for women’s intimate health. The company’s platform combines non-invasive treatment devices with software-driven patient monitoring and analytics to support pelvic floor function, address stress urinary incontinence and enhance vaginal tissue health.

EUDA Health’s core product offerings utilize low-intensity radiofrequency energy delivered through proprietary handpieces to promote tissue remodeling and muscle activation.